SG11202002192QA - Restoration of t cell activity via the cd39/cd73 axis - Google Patents
Restoration of t cell activity via the cd39/cd73 axisInfo
- Publication number
- SG11202002192QA SG11202002192QA SG11202002192QA SG11202002192QA SG11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA
- Authority
- SG
- Singapore
- Prior art keywords
- restoration
- axis
- cell activity
- activity via
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568812P | 2017-10-06 | 2017-10-06 | |
| US201862686143P | 2018-06-18 | 2018-06-18 | |
| PCT/EP2018/077217 WO2019068907A1 (en) | 2017-10-06 | 2018-10-05 | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002192QA true SG11202002192QA (en) | 2020-04-29 |
Family
ID=63799006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002192QA SG11202002192QA (en) | 2017-10-06 | 2018-10-05 | Restoration of t cell activity via the cd39/cd73 axis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190218308A1 (https=) |
| EP (1) | EP3692068B1 (https=) |
| JP (1) | JP7274469B2 (https=) |
| KR (1) | KR102710877B1 (https=) |
| CN (1) | CN111542539B (https=) |
| AU (1) | AU2018346447B2 (https=) |
| BR (1) | BR112020006809A2 (https=) |
| CA (1) | CA3074588A1 (https=) |
| IL (1) | IL273414B1 (https=) |
| SG (1) | SG11202002192QA (https=) |
| WO (1) | WO2019068907A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| GB2545676A (en) * | 2015-12-21 | 2017-06-28 | Dublin Inst Of Tech | Prediction of therapeutic response using vibrational spectroscopy |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| MY202018A (en) | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| EP3788079A4 (en) | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| DK3807316T3 (da) | 2018-06-18 | 2024-07-29 | Innate Pharma | Sammensætninger og fremgangsmåder til behandling af cancer |
| MX2021012769A (es) | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| JP7471016B2 (ja) * | 2019-08-21 | 2024-04-19 | ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド | 抗ｃｄ７３抗体およびその適用 |
| JP7727387B2 (ja) * | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| CA3165384A1 (en) * | 2019-12-19 | 2021-06-24 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| CN114106160A (zh) * | 2020-08-28 | 2022-03-01 | 安源医药科技（上海）有限公司 | 抗SARS-CoV-2病毒单克隆抗体及应用 |
| US20220133902A1 (en) * | 2020-11-04 | 2022-05-05 | Heidelberg Pharma Research Gmbh | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy |
| CA3211501A1 (en) * | 2021-02-19 | 2022-08-25 | Janssen Biotech, Inc. | Materials and methods for targeting regulatory t cells for enhancing immune surveillance |
| CN117241832A (zh) | 2021-03-19 | 2023-12-15 | 海德堡医药研究有限责任公司 | B淋巴细胞特异性的鹅膏毒素抗体缀合物 |
| MX2024010646A (es) | 2022-03-03 | 2024-09-19 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos. |
| US20250361314A1 (en) * | 2022-06-08 | 2025-11-27 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Cd39/cd73 bispecific antigen binding protein and use thereof |
| EP4683650A2 (en) * | 2023-03-21 | 2026-01-28 | Beam Therapeutics Inc. | Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof |
| CN120992939B (zh) * | 2025-10-27 | 2025-12-26 | 苏州旭光科星抗体生物科技有限公司 | 一种可溶性cd39蛋白含量检测试剂盒及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6387645B1 (en) * | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2238170B1 (en) * | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US8865653B2 (en) * | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| AU2013218017B2 (en) * | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| MA39986A (fr) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| GB2538120A (en) * | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CA3005986A1 (en) | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| CN114805575B (zh) | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| WO2017120508A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| WO2018094148A1 (en) | 2016-11-18 | 2018-05-24 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| IL269150B2 (en) * | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| KR102781619B1 (ko) * | 2017-11-15 | 2025-03-14 | 이나뜨 파르마 에스.에이. | 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체 |
| MX2021012769A (es) * | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
| CA3149494A1 (en) * | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
-
2018
- 2018-10-05 BR BR112020006809-8A patent/BR112020006809A2/pt unknown
- 2018-10-05 JP JP2020519404A patent/JP7274469B2/ja active Active
- 2018-10-05 KR KR1020207012268A patent/KR102710877B1/ko active Active
- 2018-10-05 SG SG11202002192QA patent/SG11202002192QA/en unknown
- 2018-10-05 IL IL273414A patent/IL273414B1/en unknown
- 2018-10-05 CN CN201880064186.3A patent/CN111542539B/zh active Active
- 2018-10-05 EP EP18783458.5A patent/EP3692068B1/en active Active
- 2018-10-05 WO PCT/EP2018/077217 patent/WO2019068907A1/en not_active Ceased
- 2018-10-05 CA CA3074588A patent/CA3074588A1/en active Pending
- 2018-10-05 AU AU2018346447A patent/AU2018346447B2/en active Active
-
2019
- 2019-03-29 US US16/370,726 patent/US20190218308A1/en not_active Abandoned
-
2022
- 2022-07-28 US US17/876,164 patent/US20230099801A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102710877B1 (ko) | 2024-09-26 |
| KR20200060471A (ko) | 2020-05-29 |
| EP3692068B1 (en) | 2022-12-07 |
| CN111542539B (zh) | 2023-10-20 |
| JP7274469B2 (ja) | 2023-05-16 |
| BR112020006809A2 (pt) | 2020-10-06 |
| IL273414A (en) | 2020-05-31 |
| WO2019068907A1 (en) | 2019-04-11 |
| IL273414B1 (en) | 2026-04-01 |
| AU2018346447A1 (en) | 2020-03-19 |
| CN111542539A (zh) | 2020-08-14 |
| US20190218308A1 (en) | 2019-07-18 |
| AU2018346447B2 (en) | 2025-06-19 |
| EP3692068A1 (en) | 2020-08-12 |
| US20230099801A1 (en) | 2023-03-30 |
| CA3074588A1 (en) | 2019-04-11 |
| JP2020536109A (ja) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273414A (en) | Restoration of T cell activity through the CD39/CD73 axis | |
| IL268058A (en) | Compositions and methods for depleting CD137 plus cells | |
| EP3612568B8 (en) | Cell | |
| PL3389564T3 (pl) | Proteza zastawki serca | |
| EP3322383A4 (en) | Prosthetic heart valve | |
| PL3387125T3 (pl) | Kompozycje do mycia naczyń zawierające polipeptydy posiadające aktywność beta-glukanazy oraz ich zastosowania | |
| SG11201610077TA (en) | Active panel demarcation | |
| EP3130345A4 (en) | Peptide having fibrosis inhibitory activity and composition containing same | |
| GB2551933B (en) | Paleogeographic reconstruction of an area of the earth crust | |
| EP3344156A4 (en) | Implantable nuclear prosthesis | |
| EP3638395A4 (en) | ACOUSTIC MATERIALS | |
| GB201701509D0 (en) | Pluripotenet stem cells | |
| EP3290556A4 (en) | Net-like structure | |
| EP3256124A4 (en) | Cenicriviroc for the treatment of fibrosis | |
| IL261891A (en) | Active retinal implant | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| EP3270985A4 (en) | Polypeptide compositions and methods of using the same | |
| EP3160949A4 (en) | Enzyme interacting agents | |
| SI3381457T1 (sl) | Fiziološka aktivna sestava, ki vsebuje N-acetilglukozamin za zdravljenje bolečin v hrbtu | |
| GB201710600D0 (en) | RedCloud BB1 | |
| EP3560984A4 (en) | STRUCTURAL BODY | |
| PL3461963T3 (pl) | Układ nośny i układ elementów łączących do połączenia belek | |
| PL3432728T3 (pl) | Kompozycje enzymatyczne | |
| IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
| GB201500479D0 (en) | Joint prosthesis supporting assembly |